Glenmark Pharma arm to launch breast cancer treatment injection in US market

Glenmark Pharma Ltd has announced that its wholly owned subsidiary, Glenmark Pharmaceuticals Inc., USA, will launch Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials in the US market.

The product is therapeutically equivalent to Eisai Inc.'s Halaven in the same dosage strength of 1 mg/2 mL (0.5 mg/mL), a widely prescribed oncology drug for the treatment of breast cancer, the company said in a stock exchange filing on Tuesday.

Distribution of the drug will commence in September 2025. The launch marks a key milestone for Glenmark as it represents the company’s first complex generic product in the US institutional segment.

“We are pleased to announce the launch of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials. As the first complex generic in our portfolio, this launch marks both our commitment to growing our products within the institutional channel and reinforces our dedication to bring quality and affordable alternatives to market for patients in need,” said Marc Kikuchi, President and Business Head – North America, Glenmark Pharma, on 2 September.

According to IQVIA sales data for the 12 months ended July 2025, Halaven Injection, 1 mg/2 mL (0.5 mg/mL), recorded annual sales of about $66.3 million.

The company added that Glenmark’s Eribulin Mesylate Injection single-dose vials have been approved only for the indications listed in Glenmark’s approved label.

Last month, Glenmark announced the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (single-dose vials), in the US market through its subsidiary. The product is a bioequivalent and therapeutically equivalent version of Mycamine for Injection, used to treat severe fungal infections. Distribution will also begin in September.

Shares of Glenmark Pharma Ltd were trading 0.58% lower at ₹1,915.7 on the BSE at 3:06 PM.